Publication | Open Access

Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells

Medicinal ChemistryHdac InhibitorsDrug TargetingMedicineAntimetastatic ActivitiesCancer Cell BiologyPharmacotherapyAnti-cancer AgentDrug DevelopmentPharmacologyRadiation OncologyPharmaceutical ChemistryCancer ResearchDrug DiscoveryHuman Cancer Cells